Abnormal Gene Product Associated With Prostate Cancer Generated by Unusual Mechanism
- Levels of a fusion product of the SLC45A3 and ELK4 genes correlated with prostate cancer disease progression.
- The fusion product controlled proliferation of prostate cancer cell lines.
- An unusual pathway and not chromosomal rearrangement led to fusion product expression.
PHILADELPHIA — Researchers have identified a potential new pathway in prostate cancer cells by which cancer-driving gene products can be generated, according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.
“Our work shows that cancers have many more tricks than we thought to generate potential cancer-driving genes or gene products,” said Hui Li, Ph.D., assistant professor of pathology at the University of Virginia in Charlottesville, and a recipient of an Innovative Research Grant from Stand Up To Cancer (SU2C). The AACR is the scientific partner of SU2C.
Gene fusion is a common characteristic of human cancers. In many cases, the protein products of these gene fusions, which are generated via an RNA intermediate, have a key role in the genesis of the cancer. A well-characterized example of this is the protein that drives chronic myeloid leukemia, BCR-ABL, which is generated via RNA intermediates from a fusion gene formed by chromosomal translocation — an event involving exchange of genomic DNA between two distinct chromosomes.
“For many years, chromosomal translocation was considered the sole way in which single RNAs consisting of copies of parts of two genes, so-called fusion RNAs, could be generated,” said Li. “We have shown that fusion RNAs can be generated without changes to DNA by a new mechanism that we are calling cis-SAGe [cis-splicing of adjacent genes].” Recently, a fusion RNA formed from parts of the SLC45A3 and ELK4 genes was identified in prostate cancer cells in the absence of any DNA alterations. Li and his colleagues confirmed in two prostate cancer cells lines that the SLC45A3-ELK4 fusion RNA could be detected even though there was no evidence of genomic DNA rearrangement.
Detailed molecular analysis of the prostate cancer cell lines indicated that the SLC45A3-ELK4 fusion RNA was generated by cis-SAGe. SLC45A3 and ELK4 are neighboring genes, and cis-SAGe occurred when an RNA that crossed the boundary between the two genes was formed.
The protein CCCTC-binding factor normally acts to insulate SLC45A3 and ELK4 from each other. Li and his colleagues found that levels of this protein at the gene boundary inversely correlated with the amount of SLC45A3-ELK4 fusion RNA generated, providing molecular insight into how the quantity of this fusion RNA could be regulated.
A functional role for the SLC45A3-ELK4 fusion RNA in prostate cancer was suggested by two observations. First, it promoted the growth of the two prostate cancer cell lines in culture. Second, its levels in human prostate samples correlated with prostate cancer disease progression — normal prostate tissue expressed the lowest levels and prostate cancer specimens from men with metastatic disease expressed the highest levels.
“These data are not sufficient to say that the SLC45A3-ELK4 fusion RNA has a causal role in prostate cancer,” said Li. “But they are highly suggestive, and I am very excited that this high-risk project, which I would not have been able to pursue without the grant from Stand Up To Cancer, has uncovered what seems to be a new way in which cancer can be driven.”
About the AACR
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR’s membership includes 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes seven peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of individual and team science grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer.
For more information about the AACR, visit www.AACR.org.
About Stand Up To Cancer
Stand Up To Cancer (SU2C) – a program of the Entertainment Industry Foundation (EIF), a 501(c) (3) charitable organization – raises funds to accelerate the pace of groundbreaking translational research that can get new therapies to patients quickly and save lives. SU2C facilitates collaboration among the best and the brightest in the cancer research community. The American Association for Cancer Research (AACR) and a Scientific Advisory Committee conduct rigorous, competitive review processes through which SU2C’s grantees are selected. By galvanizing the entertainment industry, SU2C generates awareness and builds grassroots support for this new approach to ending cancer.
Stand Up To Cancer was founded by a group of media, entertainment and philanthropic leaders whose lives have been affected by cancer in significant ways. Members of SU2C’s Executive Leadership Council include Sherry Lansing, chairperson of the Entertainment Industry Foundation’s (EIF) Board of Directors and founder of the Sherry Lansing Foundation; EIF President and CEO Lisa Paulsen; Katie Couric; EIF Senior Vice President Kathleen Lobb; Rusty Robertson and Sue Schwartz of the Robertson Schwartz Agency; Pam Williams, partner at Laura Ziskin Productions; and nonprofit executive Ellen Ziffren. The late Laura Ziskin, a legendary film producer who executive produced the 2008 and 2010 SU2C telecasts, was also a co-founder of Stand Up To Cancer.